American Vertex Pharmaceuticals Inc. has entered into an agreement to acquire Crinetics Pharmaceuticals Inc. in order to expand its development in the field of endocrinology. This is reported in a press release. Vertex.
The deal is valued at $10 billion ($85 per share, which is 102% higher than the closing price on July 6). The financing of the deal involves the attraction of a bridge loan of $4.5 billion from Bank of America and Morgan Stanley. The deal exceeds the buyout of assets of Alpine Immune Sciences for $4.4 billion in 2024.
The transaction is expected to be completed in the third quarter of 2026. The flagship asset Crinetics is a Palsonify drug for the treatment of a rare pituitary gland disease. In addition, the company is developing a therapy for the genetic disease congenital adrenal hyperplasia. Both drugs can generate more than $5 billion in annual revenue.
Vertex has developed the drug Trikafta for the treatment of cystic fibrosis, an inherited disease caused by a mutation of the CFTR gene, which generated revenue of $10.3 billion in 2025 (85% of the company's total revenue). At the same time, Vertex aims to achieve a similar effect in other segments, including the drug Casgevy for the treatment of anemia and beta-thalassemia.
Vertex cooperates with CRISPR Therapeutics, Moderna, Entrada Therapeutics and other companies in the field of rare disease treatment.
Vertex Pharmaceuticals Inc. is an American biotech company developing and selling drugs for the treatment of immune diseases. The company is headquartered in Boston, Massachusetts. Revenue totaled $12 billion in 2025.
Crinetics Pharmaceuticals, Inc. is a biopharmaceutical company developing drugs for the treatment of rare endocrine diseases and tumors related to the endocrine system. The company is headquartered in San Diego, California.
Read our Telegram channel "Mergers and acquisitions. AK&M».
Our channel at MAX is "Mergers and Acquisitions. AK&M».
